WO2012112013A3 - A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer - Google Patents

A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer Download PDF

Info

Publication number
WO2012112013A3
WO2012112013A3 PCT/KR2012/001264 KR2012001264W WO2012112013A3 WO 2012112013 A3 WO2012112013 A3 WO 2012112013A3 KR 2012001264 W KR2012001264 W KR 2012001264W WO 2012112013 A3 WO2012112013 A3 WO 2012112013A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoantibody
breast cancer
present
complex
antigen
Prior art date
Application number
PCT/KR2012/001264
Other languages
French (fr)
Other versions
WO2012112013A2 (en
Inventor
Eun Wie Cho
Chang Gyu HEO
Jeong Heon Ko
Mi Kyung Woo
Hyang Sook Yoo
Hai Min Hwang
Original Assignee
Korea Research Institute Of Bioscience And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120011503A external-priority patent/KR101374758B1/en
Application filed by Korea Research Institute Of Bioscience And Biotechnology filed Critical Korea Research Institute Of Bioscience And Biotechnology
Priority to US14/000,221 priority Critical patent/US9234893B2/en
Priority to CN201280013908.5A priority patent/CN103429617B/en
Publication of WO2012112013A2 publication Critical patent/WO2012112013A2/en
Publication of WO2012112013A3 publication Critical patent/WO2012112013A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a cytokeratin 8/18 complex-specific autoantibody or a fragment comprising an antigen-binding site (paratope) thereof, the use thereof in the diagnosis of breast cancer, a polypeptide having an amino acid sequence of an epitope specifically binding to the autoantibody, a composition for diagnosing breast cancer comprising an agent capable of measuring an expression level of the autoantibody or the fragment comprising an antigen-binding site thereof, a hybridoma cell line producing the autoantibody, and a kit for diagnosing breast cancer comprising the composition of the present invention. Further, the present invention relates to a method for diagnosing breast cancer, comprising the step of detecting the cytokeratin 8/18 complex-specific autoantibody or the fragment comprising the antigen-binding site thereof using the composition of the present invention, and a method for screening a therapeutic agent for breast cancer using the autoantibody.
PCT/KR2012/001264 2011-02-18 2012-02-20 A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer WO2012112013A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/000,221 US9234893B2 (en) 2011-02-18 2012-02-20 Marker comprising anti-CK8/18 complex autoantibody and its use for diagnosing cancer
CN201280013908.5A CN103429617B (en) 2011-02-18 2012-02-20 Comprise the anti-marker of CK8/18 mixture autoantibody and the purposes of diagnosing cancer thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110014809 2011-02-18
KR10-2011-0014809 2011-02-18
KR10-2012-0011503 2012-02-03
KR1020120011503A KR101374758B1 (en) 2011-02-18 2012-02-03 A marker comprising anti-CK8/18 complex autoantibodies and a composition comprising antigen thereof for diagnosing cancer

Publications (2)

Publication Number Publication Date
WO2012112013A2 WO2012112013A2 (en) 2012-08-23
WO2012112013A3 true WO2012112013A3 (en) 2012-12-06

Family

ID=46673071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001264 WO2012112013A2 (en) 2011-02-18 2012-02-20 A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer

Country Status (1)

Country Link
WO (1) WO2012112013A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374758B1 (en) 2011-02-18 2014-03-17 한국생명공학연구원 A marker comprising anti-CK8/18 complex autoantibodies and a composition comprising antigen thereof for diagnosing cancer
SE538211C2 (en) 2013-04-05 2016-04-05 Idl Biotech Ab Method for detecting cytokeratin 8, 18 and / or 19 and / or soluble fragments thereof
CN110333352A (en) * 2019-08-07 2019-10-15 基因科技（上海）股份有限公司 Tumour related auto-antibodies and tumor markers combined detection kit
CN110470848A (en) * 2019-08-23 2019-11-19 安徽恩禾生物技术有限公司 A kind of MBP ELISA antibody assay kit and preparation method thereof
CN116478285B (en) * 2023-01-20 2024-03-12 上海大格生物科技有限公司 Diagnostic mouse-derived anti-human CK antibody and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20090311193A1 (en) * 2006-03-23 2009-12-17 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
KR20100118900A (en) * 2009-04-29 2010-11-08 한국생명공학연구원 Cytokeratin17-specific human antibody
KR20110040624A (en) * 2009-10-12 2011-04-20 한국생명공학연구원 A marker comprising anti-fasn autoantibodies and a composition comprising antigen thereof for diagnosing liver cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20090311193A1 (en) * 2006-03-23 2009-12-17 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
KR20100118900A (en) * 2009-04-29 2010-11-08 한국생명공학연구원 Cytokeratin17-specific human antibody
KR20110040624A (en) * 2009-10-12 2011-04-20 한국생명공학연구원 A marker comprising anti-fasn autoantibodies and a composition comprising antigen thereof for diagnosing liver cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLUEMKE, K. ET AL.: "Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with Prognosis", CANCER EPIDEMIOL BIOMARKERS PREV., vol. 18, no. 8, 5 August 2009 (2009-08-05), pages 2190 - 2194 *
CIMPEAN, A. M. ET AL.: "Relevance of the immunohistochemical expression of cytokeratin 8/18 for the diagnosis and classification of breast cancer", ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, vol. 49, no. 4, 2008, pages 479 - 483 *
MULLIGAN, A. M. ET AL.: "CK8/18 Expression, the Basal Phenotype, and Family History in Identifying BRCAl-Associated Breast Cancer in the Ontario Site of the Breast Cancer Family Registry", CANCER, 2 November 2010 (2010-11-02), pages 1350 - 1359 *

Also Published As

Publication number Publication date
WO2012112013A2 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
MX2009009450A (en) He4 monoclonal antibodies and methods for their use.
HRP20192347T1 (en) Antibodies against claudin 18.2 useful in cancer diagnosis
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
JP2017518366A5 (en)
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2012106556A3 (en) Methods and compositons relating to inhibition of igf-1r
EA030777B9 (en) Anti-alpha synuclein binding molecules
EP2352523A4 (en) Improved anti-cd19 antibodies
EA201591091A1 (en) Antigen-binding proteins for BCMA
NZ595340A (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
BR112012007365A2 (en) il-1 binding proteins
EA201001874A1 (en) A METHOD FOR DIAGNOSTIC MALIGNANT NUMER FORMATION, EXPRESSING THE HER2 RECEPTOR OR HIS REDUCED OPTIONS
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
AR076655A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO THE COMPLEMENT PROTEIN C3B
WO2012112013A3 (en) A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer
JP2017508475A5 (en)
WO2009113814A3 (en) Protein marker for early diagnosis of liver cancer
WO2009019365A3 (en) Ezrin assay method for the in vitro diagnosis of colorectal cancer
MX2015003150A (en) Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
BRPI0812488A2 (en) HUMANIZED AND CHEMICAL ANTI-BODIES ANTIBODIES MEDIATION OF CANCER CELL, USES OF THE SAME, CONNECTION TESTS, METHODS, COMPOSITIONS AND TEST KIT
WO2011091113A3 (en) Detection of early-stage pancreatic adenocarcinoma
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
BR112015001102A2 (en) A detecting method of cancer
DK2054443T3 (en) Antibodies to an epitope from AGR2, assays and hybridomas
WO2011046309A3 (en) A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12747333

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14000221

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12747333

Country of ref document: EP

Kind code of ref document: A2